<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831840</url>
  </required_header>
  <id_info>
    <org_study_id>20201198</org_study_id>
    <nct_id>NCT04831840</nct_id>
  </id_info>
  <brief_title>Recurrent Urinary Tract Infections and the Microbiome</brief_title>
  <official_title>Is PCR Amplification More Sensitive Than Urine Cultures in Diagnosing Urinary Tract Infections in Patients With Recurrent Bladder Infections?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if polymerase chain reaction (PCR) (UTIPâ„¢) is more&#xD;
      sensitive in identifying urinary tract infections (UTI's) than standard urine cultures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of uropathogens</measure>
    <time_frame>Day 1</time_frame>
    <description>The proportion of uropathogens found on PCR versus urine culture from urine samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients negative for repeat testing</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The proportion of negative patient on repeat testing of urine samples.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Recurrent Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Female participants with recurrent urinary tract infections (RUTI).</arm_group_label>
    <description>Patients with RUTIs (Group A) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female control patients without RUTIs</arm_group_label>
    <description>Patients without RUTIs (Group B) will provide two urine samples. One urine sample is a clean catch and the other is a catheterized specimen. Both will be sent for analysis. A perineal swab will also be collect and analyzed for each patient.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with RUTIs and controls will be enrolled from University of Miami's or Holy&#xD;
        Cross Hospital's female pelvic medicine and reconstructive surgery clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 y/o-90 y/o&#xD;
&#xD;
          -  Able to consent&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Group A only: Recurrent UTI (2 UTIs in 6 months)&#xD;
&#xD;
          -  Group B only: No history of recurrent UTIs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Pelvic radiation&#xD;
&#xD;
          -  Urinary retention (&gt;200 ml residual)&#xD;
&#xD;
          -  Greater than Stage 2 prolapse&#xD;
&#xD;
          -  Renal calculi&#xD;
&#xD;
          -  Immunosuppressed&#xD;
&#xD;
          -  Neurologic disorder with significant bladder impairment&#xD;
&#xD;
          -  No current UTI via dip stick&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Martin, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Martin, DO</last_name>
    <phone>3052436590</phone>
    <email>lem114@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GW Davila, MD</last_name>
      <phone>954-229-8660</phone>
      <email>gwilly.davila@holy-cross.com</email>
    </contact>
    <investigator>
      <last_name>GW Davila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Martin, DO</last_name>
      <phone>305-243-6590</phone>
      <email>lem114@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Martin, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Laura Martin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

